IAXC 2022 logo The 24th International AIDS Conference
Montreal,  Juli 2022

 Die 24. WeltAidsKonferenz findet im kanadischen Montreal unter dem Motto „Re-engage and follow the science” statt. Die Welt hat die vor Corona gesetzten Ziele aus den Augen verloren und soll sich wieder im Kampf gegen HIV/Aids engagieren. Neben den politischen Themen werden aber auch wissenschaftliche Studien vorgestellt werden zu Therapie, PEP und PrEP sowie STI inklusive Affenpocken.

https://aids2022.org/

PDF/PPT zum Download ppt pdf

TAF und Gewicht

Langzeit-Daten belegen mittlerweile die Gewichtszunahme unter TAF.weiter

Integrasehemmer und Gewicht

Auch die Integrasehemmer der zweiten Generation sind mit einer verstärkten Gewichtszunahme assoziiert.weiter

ART LA und Gewicht

Gepoolte Daten aus den Studien FLAIR und ATLAS, in denen Cabotegravir+Rilpivirin LA mit Dolutegravir/Abacavir/Lamivudin verglichen wurde...weiter

Real World und Gewicht in Afrika

Der Gewichtsverlauf von 7047 Personen in Zimbabwe, die 2008-2021 eine ART begonnen bzw. das Regime gewechselt hatten...weiter

ART LA intramuskulär in den Oberschenkel

Eine Alternative zur intramuskulären Injektion von Cabotegravir/Rilpivirin LA ...weiter

CARLOS: Daten zur ART LA aus der Praxis

In der deutschen Beobachtung CARLOS war der häufigste Grund für den Wechsel auf Cabotegravir+Rilpivirin LA nach Ansicht der Ärzt*innen ...weiter

ALLIANCE: B/F/TAF vs DOL+F/TDF bei HIV/HBV

In der laufenden Phase-3-Studie ALLIANCE wird die Fixkombination B/F/TAF gegen DOL + F/TDF mit HIV/HBV-Koinfektion geprüft. weiter

HIV-Heilung

Erneut Patient geheilt nach Knochenmark-Transplantation weiter

Sexuell übertragbare Infektionen

Doxycyclin nach dem Sex vermindert das STI-Risiko um rund 60% weiter


PDF/PPT zum Download ppt pdf

Gilead internal datasets

1. BIC/FTC/TAF

2. TAF

2. Lenacapavir (LEN)

3. HIV Cure

4. Prevention

Gilead investigator sponsored research (ISR) and collaborative studies

A. BIC/FTC/TAF

B. TAF

C. Comorbidities

D. Prevention




ViiV Healthcare

DOLUTEGRAVIR-based regimens

Efficacy and Safety of Switching to Dolutegravir/Lamivudine by Baseline Regimen in Virologically Suppressed Adults: 48-Week Pooled Analysis

Scholten et al.
Poster

View Poster

View poster & listen to audio presentation

Changes in Inflammatory Biomarkers and Baseline Variables After Switching to Dolutegravir/Lamivudine (DTG/3TC) in 2 Randomized Clinical Trials of Virologically Suppressed Adults: 48-Week Pooled Analysis

Llibre et al.
Poster

View Poster

View poster & listen to audio presentation

Efficacy and Safety of Switching to Dolutegravir/Lamivudine (DTG/3TC) in Treatment-Experienced, Virologically Suppressed PLHIV Aged ≥50 Years: Pooled Results From the TANGO and SALSA Studies

Walmsley et al.
Poster

View Poster

View poster & listen to audio presentation

Low Level of Virologic Failure and Resistance in ART-Experienced, Integrase Inhibitor-Naive Participants Receiving Dolutegravir (DTG) and Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Combined Regimens: 10-Year Follow-up in the SAILING Study

Wang et al.
Poster

View Poster

View poster & listen to audio presentation

Switching to Dolutegravir/Lamivudine Two-Drug Regimen: Durability and Virologic Outcomes in Routine US Clinical Care

Pierone et al.
Poster

View Poster

View poster & listen to audio presentation

A Multicentre Observational Study to Determine the Safety and Effectiveness of Dolutegravir (DTG) Use During Pregnancy: Data From DOLOMITE-NEAT ID Network Study

Kowalska et al.
Poster

View Poster

View poster & listen to audio presentation

Treatment Experience of Single-Tablet Dolutegravir/Lamivudine in the United States: Results From the ‘Real-world Outcomes With Dolutegravir-Based Two-Drug-Regimens Dovato and Juluca for the Treatment of HIV-1’ (TANDEM Study)

Schneider et al.
Poster

View Poster

View poster & listen to audio presentation

Improvements in Patient-Reported Outcomes in Older Adults Aged ≥50 Years With HIV-1 After Switching to a 2-Drug Regimen of Fixed-Dose Combination DTG/3TC: 48-Week Results From the SALSA Study

Kumar et al.
Poster

View Poster

View poster & listen to audio presentation

Expedited Development and Registration Resulting in Successful Uptake of Generic, Pediatric Dolutegravir Products for Low- and Middle-Income Countries Through an Innovative Public-Private Partnership*

Louey et al.
Poster

Access this presentation via the AIDS 2022 conference website

CABOTEGRAVIR + RILPIVIRINE for treatment

Safety and Effectiveness Outcomes From the CARISEL Study: Phase 3b Hybrid-3 Implementation Study Integrating Cabotegravir + Rilpivirine Long-Acting Into European Clinical Settings

Jonsson-Oldenbüttel et al.
Poster

View Poster

View poster & listen to audio presentation

Long-Acting Cabotegravir + Rilpivirine Injection Site Reactions: Pooled Week 96 Results

Chamay et al.
Poster

View Poster

View poster & listen to audio presentation

Long-Acting Cabotegravir + Rilpivirine in Older Adults: Pooled Phase 3 Week 96 Results

Elliot et al.
Poster

View Poster

View poster & listen to audio presentation

“Give It a Shot”: Best Practices From HCPs for Administering Long-Acting CAB + RPV

Teichner et al.
Poster

View Poster

View poster & listen to audio presentation

Initiating Long-Acting Cabotegravir and Rilpivirine in a Real-world setting – Clinical Characteristics and Switch Reasons From PLHIV and Health Care Provider Perspective in the German CARLOS Cohort

Wyen et al.
Poster

View Poster

View poster & listen to audio presentation

Week 96 Weight and Lipid Changes From Baseline Among Participants Receiving Cabotegravir and Rilpivirine Long-Acting or Comparator Therapy in the ATLAS-2M and FLAIR Studies

Patel et al.
Poster

View Poster

View poster & listen to audio presentation

Pharmacokinetics (PK) and Tolerability of Cabotegravir (CAB) and Rilpivirine (RPV) Long-Acting (LA) Intramuscular (IM) Injections to the Vastus Lateralis (Lateral Thigh) Muscles of Healthy Adult Participants

Han et al.
Poster

View Poster

View poster & listen to audio presentation

Factors Associated With Healthcare Providers’ Preference for Forgoing an Oral Lead-in Phase When Initiating Long-Acting Injectable ART in the SOLAR Clinical Trial

Karver et al.
Poster

View Poster

View poster & listen to audio presentation

A Study Evaluating the Safety, Tolerability and Pharmacokinetics of a High-Concentration (CAB 400 mg/mL) Cabotegravir Long-Acting Injectable Formulation Following Subcutaneous and Intramuscular Administration in Healthy Adult Participants

Benn et al.
Poster

View Poster

View poster & listen to audio presentation

CABOTEGRAVIR for prevention

The Relative Cost-effectiveness of Long-Acting Injectable Cabotegravir Versus Oral Pre-exposure Prophylaxis: A Modelled Economic Evaluation and Threshold Analysis in South Africa Based on the HPTN 083 and 084 Trials*

Meyer-Rath et al.
Oral Presentation

Access this presentation via the AIDS 2022 conference website

Long Acting Cabotegravir: Updated Efficacy and Safety Results From HPTN 084*

Delany-Moretlwe et al.
Oral Presentation

Access this presentation via the AIDS 2022 conference website

Transgender Women (TGW) in HPTN 083: An Evaluation of Safety, Efficacy, and Gender Affirming Hormonal Therapy (GAHT) Interactions With Long-Acting Cabotegravir (CAB-LA)*

Grinsztejn et al.
Poster

Access this presentation via the AIDS 2022 conference website

Willingness and Preferences for Long-Acting Injectable PrEP Among US Men Who Have Sex With Men

Beckham et al.
Poster

View poster

View poster & listen to audio presentation

Audience Segmentation of Preferences for Long-Acting Injectable PrEP Among US MSM: A Latent Class Analysis

Beckham et al.
Poster

View poster

View poster & listen to audio presentation

Supporting Achievement of the State of Georgia’s 25% HIV Incidence Reduction Target Among MSM: A Mathematical Model to Evaluate the Potential Impact of Long-Acting Preexposure Prophylaxis in Atlanta

Blissett et al.
Poster

View poster

View poster & listen to audio presentation

Selection of Cabotegravir Dosing Regimens for HIV Treatment and Pre-exposure Prophylaxis (PrEP) in Adolescents by Leveraging Adult Data*

Han et al.
Poster

View poster

View poster & listen to audio presentation

Acceptability of Injectable Versus Daily Oral Pills for HIV Prevention: Lesson From HPTN 084 *

Tolley et al.
Poster

Access this presentation via the AIDS 2022 conference website

Fostemsavir

Efficacy and Safety of Fostemsavir Plus Optimized Background Therapy in Heavily Treatment-Experienced Adults With HIV-1: Week 240 Results of the Phase 3 BRIGHTE Study

Aberg et al.
Poster

View poster

View poster & listen to audio presentation

Other HIV-related content

Bridging the Gap Between Patient Perceptions and Delivered Care Among People Living With HIV in the Asian Region

Park et al.
Poster

View poster

View poster & listen to audio presentation

Implementation of Telemedicine for HIV Care in the Public Health System of Buenos Aires, Argentina: A Qualitative Study Based on Surveys Among Health Workers to Assess Acceptability of This Strategy*

Bullo et al.
Poster

View poster

View poster & listen to audio presentation

Do ART and Chemsex Drugs Get Along? Potential Drug-Drug Interactions in a Cohort of HIV-Positive Chemsex Users*

de la Mora et al.
Poster

View poster

View poster & listen to audio presentation

U=U Awareness Promotes Engagement in HIV Care Among HIV Negative Men Who Have Sex With Men in Mississippi and Alabama*

Mckay et al.
Poster

View poster

View poster & listen to audio presentation

Differences in Burden of Internalized HIV Stigma (IHS) by Race/Ethnicity Among People With HIV (PWH) Living in the US*

Drumright et al.
Poster

View poster

View poster & listen to audio presentation

Does Travel Time Matter?: Transportation Vulnerability and Access to HIV Care Among People Living With HIV in South Carolina*

Hung et al.
Poster

View poster

View poster & listen to audio presentation

Implementation of a Ridesharing Intervention to Address Transportation Vulnerability for People Living With HIV in the Southern United States: Qualitative Findings on Acceptability and Feasibility*

Harrison et al.
Poster

View poster

View poster & listen to audio presentation

*denotes ViiV-supported studies


Meldungen

  • RSV

    09. Oktober 2024: Krankenkassen zahlen RSV-Impfung für ältere Erwachsene weiter

  • Influenza

    09. Oktober 2024: CDC: Aktuelle Vakzine verhindert ein Drittel der Krankenhauseinweisungen weiter

  • Salmonellen

    06. Oktober 2024: Ausbruch vermutlich durch kontaminierten Rucola weiter

  • Vogelgrippe

    06. Oktober 2024: Übertragung bei Kühen nicht respiratorisch weiter

  • HIV-PrEP

    04. Oktober 2024: Gilead schließt Lizenzvereinbarungen zu Lenacapavir. weiter

  • Newletter online

    Jeden Monat akutelle Informationen rund ums Thema HIV und sexuell übertragbare Erkrankungen.

    Für Ärzt_innen, Menschen mit HIV und alle Interessierten.

    Anmeldung hier

  • COVID-19

    23. September 2024: Neue Variante XEC weiter

  • PrEP

    17. September 2024: Lenacapavir senkt HIV-Risiko bei MSM um 96%. weiter

  • HIV

    09. September 2024: Krebsrisiko nach Organtransplantation weiter

  • Vogelgrippe

    09. September 2024: Erste H5-Transmission ohne Tierkontakt weiter

  • MPOX

    09. September 2024: Empfehlungen der STAKOB weiter

  • HIV-Heilung

    06. September 2024: Christian Gaebler erhält ERC Starting Grant weiter

  • Impfung

    05. September 2024: Dreifach-Grippeimpfstoffe und RSV-Impfung für Ältere jetzt Kassenleistung weiter

  • Post-COVID-Syndrom

    05. September 2024: BMBF-geförderte Medikamentenstudie startet weiter

  • PrEP

    05. September 2024: Bessere Adhärenz bei Infektiolog*innen weiter

  • Hepatitis C

    02. September 2024: Nach wie vor hohe Reinfektionsrate in New York City weiter

Ältere Meldungen weiter

Diese Website bietet aktuelle Informationen zu HIV/Aids sowie zur HIV/HCV-Koinfektion. Im Mittelpunkt stehen HIV-Test, Symptome und Auswirkungen der HIV-Infektion, Behandlung der HIV-Infektion, HIV-Medikamente mit Nebenwirkungen und Komplikationen, Aids, Hepatitis B und C. Ein Verzeichnis der Ärzte mit Schwerpunkt HIV ergänzt das Angebot.